Hematologic safety of caplacizumab in immune-mediated thrombotic thrombocytopenic purpura: insights from platelet-related signal detection in the FAERS database
{{output}}
Background: Caplacizumab, a nanobody targeting von Willebrand factor, has transformed the management of immune-mediated thrombotic thrombocytopenic purpura (iTTP) by rapidly restoring platelet counts and improving survival. Howev... ...
